Skip to main content

Advertisement

SpringerLink
Log in

Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

Interest in TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic has been high since its first description. Recently, the use of histone deacetylase inhibitors (HDACi) to treat cancer has progressed from the laboratory to the clinic, and the combination of HDACi and TRAIL is very powerful in killing human tumors. Using a panel of prostate tumor cell lines (ALVA-31, DU-145, and LNCaP) with varying TRAIL sensitivity, we examined their sensitization to a recombinant adenovirus encoding TRAIL (Ad5-TRAIL) by sodium butyrate and trichostatin A. HDACi treatment increased coxsackie-adenovirus receptor (CAR) expression, resulting in increased adenoviral infection, and increased TRAIL-mediated killing. In TRAIL-resistant DU-145 cells, HDAC inhibition also decreased protein kinase casein kinase (PKCK) 2 activity, leading to caspase-2 activation. The importance of PKCK2 and caspase-2 in DU-145 sensitization was demonstrated with the PKCK-2-specific inhibitor, which enhanced Ad5-TRAIL-induced death, or the caspase-2-specific inhibitor, zVDVAD, which blocked Ad5-TRAIL-induced death. Thus, our data highlight the connection between HDAC inhibition of PKCK2 activity and tumor cell sensitivity to TRAIL-induced apoptosis. Specifically, HDAC inhibition leads to decreased PCKC2 activity, which is followed by caspase-2 activation and partial cleavage of caspase-8 that sensitizes the tumor cell to TRAIL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Tripathy SK, Black HB, Goldwasser E, Leiden JM (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 2:545-50

    Article  PubMed  CAS  Google Scholar 

  2. Timme TL, Hall SJ, Barrios R, Woo SL, Aguilar-Cordova E, Thompson TC (1998) Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther 5:74–82

    PubMed  CAS  Google Scholar 

  3. Baratin M, Ziol M, Romieu R, et al (2001) Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther 8:193–202

    PubMed  CAS  Google Scholar 

  4. Rosenfeld MA, Yoshimura K, Trapnell BC, et al (1992) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143–155

    Article  PubMed  CAS  Google Scholar 

  5. Akli S, Caillaud C, Vigne E et al (1993) Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 3:224–228

    Article  PubMed  CAS  Google Scholar 

  6. Le Gal La Salle G, Robert JJ, Berrard S, et al (1993) An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259:988–990

    Article  PubMed  CAS  Google Scholar 

  7. Cordier L, Duffour MT, Sabourin JC et al (1995) Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2:16–21

    PubMed  CAS  Google Scholar 

  8. Bergelson JM, Cunningham JA, Droguett G, et al (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323

    Article  PubMed  CAS  Google Scholar 

  9. Harrison GS, Glode LM (1997) Current challenges of gene therapy for prostate cancer. Oncology (Williston Park) 11:845–850, 56; discussion 56–58, 61

    Google Scholar 

  10. Hrouda D, Perry M, Dalgleish AG (1999) Gene therapy for prostate cancer. Semin Oncol 26:455–471

    PubMed  CAS  Google Scholar 

  11. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT (2000) The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 60: 5031–5036

    PubMed  CAS  Google Scholar 

  12. Rauen KA, Sudilovsky D, Le JL, et al (2002) Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma:potential relevance to gene therapy. Cancer Res 62:3812–3818

    PubMed  CAS  Google Scholar 

  13. Sachs MD, Ramamurthy M, Poel H, et al (2004) Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 11:477–486

    Article  PubMed  CAS  Google Scholar 

  14. Zhang XD, Gillespie SK, Borrow JM, Hersey P (2003) The histone deacetylase inhibitor suberic bishydroxamate:a potential sensitizer of melanoma to TNF–related apoptosis–inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66: 1537–1545

    Article  PubMed  CAS  Google Scholar 

  15. Neuzil J, Swettenham E, Gellert N (2004) Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase:role of Bcl–xL down–regulation. Biochem Biophys Res Commun 314:186–191

    Article  PubMed  CAS  Google Scholar 

  16. Rosato RR, Almenara JA, Dai Y, Grant S (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor–related apoptosis–inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2:1273–1284

    PubMed  CAS  Google Scholar 

  17. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL–R2 and sensitize apoptosis induced by TRAIL/APO2–L in human malignant tumor cells. Oncogene 23:6261–6271

    Article  PubMed  CAS  Google Scholar 

  18. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL (2000) Adenoviral–mediated transfer of the TNF–related apoptosis–inducing ligand/Apo–2 ligand gene induces tumor cell apoptosis. J Immunol 165:2886–2894

    PubMed  CAS  Google Scholar 

  19. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo–2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687–12690

    Article  PubMed  CAS  Google Scholar 

  20. Wiley SR, Schooley K, Smolak PJ, et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682

    Article  PubMed  CAS  Google Scholar 

  21. Gliniak B, Le T (1999) Tumor necrosis factor–related apoptosis–inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT–11. Cancer Res 59:6153–6158

    PubMed  CAS  Google Scholar 

  22. Walczak H, Miller RE, Ariail K, et al (1999) Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo. Nat Med 5:157–163

    Article  PubMed  CAS  Google Scholar 

  23. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL (2000) A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7:1034–1038

    Article  PubMed  CAS  Google Scholar 

  24. Martin SJ, Reutelingsperger CP, McGahon AJ, et al (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus:inhibition by overexpression of Bcl–2 and Abl. J Exp Med 182:1545–1556

    Article  PubMed  CAS  Google Scholar 

  25. VanOosten RL, Moore JM, Karacay B, Griffith TS (2005) Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo–2L–induced apoptosis by enhancing TRAIL–R2 expression. Cancer Biology & Therapy 4:1104–1112

    Article  CAS  Google Scholar 

  26. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR:the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 94:3352–3356

    Article  PubMed  CAS  Google Scholar 

  27. Richon VM, O’Brien JP (2002) Histone deacetylase inhibitors:a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8:662–664

    PubMed  Google Scholar 

  28. Hemminki A, Kanerva A, Liu B, et al (2003) Modulation of coxsackie–adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63:847–853

    PubMed  CAS  Google Scholar 

  29. VanOosten RL, Moore JM, Ludwig AT, Griffith TS (2005) Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11:542–552

    Article  PubMed  CAS  Google Scholar 

  30. Griffith TS, Broghammer EL (2001) Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 4:257–266

    Article  PubMed  CAS  Google Scholar 

  31. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S (2006) Adenovirus–mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL–induced apoptosis. Cancer Gene Ther 13:21–31

    Article  PubMed  CAS  Google Scholar 

  32. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S (2000) Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti–Fas–mediated cytotoxicity. Int J Oncol 17:1213–1218

    PubMed  CAS  Google Scholar 

  33. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7:646–657

    Article  PubMed  CAS  Google Scholar 

  34. Roy S, Packman K, Jeffrey R, Tenniswood M (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12:482–491

    Article  PubMed  CAS  Google Scholar 

  35. Jin Z, Dicker DT, El–Deiry WS (2002) Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 1: 82–89

    PubMed  CAS  Google Scholar 

  36. Izeradjene K, Douglas L, Delaney A, Houghton JA (2004) Influence of casein kinase II in tumor necrosis factor–related apoptosis–inducing ligand–induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 10: 6650–6660

    Article  PubMed  CAS  Google Scholar 

  37. Izeradjene K, Douglas L, Delaney A, Houghton JA (2005) Casein kinase II (CK2) enhances death–inducing signaling complex (DISC) activity in TRAIL–induced apoptosis in human colon carcinoma cell lines. Oncogene 24:2050–2058

    Article  PubMed  CAS  Google Scholar 

  38. Ravi R, Bedi A (2002) Sensitization of tumor cells to Apo2 ligand/TRAIL–induced apoptosis by inhibition of casein kinase II. Cancer Res 62:4180–4185

    PubMed  CAS  Google Scholar 

  39. Wang G, Ahmad KA, Ahmed K (2006) Role of protein kinase CK2 in the regulation of tumor necrosis factor–related apoptosis inducing ligand–induced apoptosis in prostate cancer cells. Cancer Res 66:2242–2249

    Article  PubMed  CAS  Google Scholar 

  40. Shin S, Lee Y, Kim W, Ko H, Choi H, Kim K (2005) Caspase–2 primes cancer cells for TRAIL–mediated apoptosis by processing procaspase–8. EMBO J 24:3532–3542

    Article  PubMed  CAS  Google Scholar 

  41. Ruzzene M, Penzo D, Pinna LA (2002) Protein kinase CK2 inhibitor 4,5,6,7–tetrabromobenzotriazole (TBB) induces apoptosis and caspase–dependent degradation of haematopoietic lineage cell–specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41–47

    PubMed  CAS  Google Scholar 

  42. Ashkenazi A, Pai RC, Fong S, et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–162

    Article  PubMed  CAS  Google Scholar 

  43. Denis LJ (2000) The role of active treatment in early prostate cancer. Radiother Oncol 57:251–258

    Article  PubMed  CAS  Google Scholar 

  44. Stone NN, Stock RG (2000) Prostate brachytherapy in patients with prostate volumes >/= 50 cm (3):dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 46:1199–1204

    Article  PubMed  CAS  Google Scholar 

  45. Steiner MS, Gingrich JR (2000) Gene therapy for prostate cancer:where are we now? J Urol 164:1121–1136

    Article  PubMed  CAS  Google Scholar 

  46. Bai M, Harfe B, Freimuth P (1993) Mutations that alter an Arg–Gly–Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell–rounding activity and delay virus reproduction in flat cells. J Virol 67:5198–5205

    PubMed  CAS  Google Scholar 

  47. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309–319

    Article  PubMed  CAS  Google Scholar 

  48. Dmitriev I, Krasnykh V, Miller CR, et al (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor–independent cell entry mechanism. J Virol 72:9706–9713

    PubMed  CAS  Google Scholar 

  49. Li Y, Pong RC, Bergelson JM et al (1999) Loss of adenoviral receptor expression in human bladder cancer cells:a potential impact on the efficacy of gene therapy. Cancer Res 59: 325–330

    PubMed  CAS  Google Scholar 

  50. Miller CR, Buchsbaum DJ, Reynolds PN et al (1998) Differential susceptibility of primary and established human glioma cells to adenovirus infection:targeting via the epidermal growth factor receptor achieves fiber receptor–independent gene transfer. Cancer Res 58:5738–5748

    PubMed  CAS  Google Scholar 

  51. Pong RC, Lai YJ, Chen H, et al (2003) Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 63:8680–8686

    PubMed  CAS  Google Scholar 

  52. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer:causes and therapies. Nat Rev Cancer 1:194–202

    Article  PubMed  CAS  Google Scholar 

  53. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126–133

    Article  PubMed  CAS  Google Scholar 

  54. Johnstone RW (2002) Histone–deacetylase inhibitors:novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287–299

    Article  PubMed  CAS  Google Scholar 

  55. Kischkel FC, Hellbardt S, Behrmann I, et al (1995) Cytotoxicity–dependent APO–1 (Fas/CD95)–associated proteins form a death–inducing signaling complex (DISC) with the receptor. EMBO J 14:5579–5588

    PubMed  CAS  Google Scholar 

  56. Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM (1995) FADD, a novel death domain–containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505–512

    Article  PubMed  CAS  Google Scholar 

  57. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845–853

    Article  PubMed  CAS  Google Scholar 

  58. Itoh N, Nagata S (1993) A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268:10932–10937

    PubMed  CAS  Google Scholar 

  59. Medema JP, Scaffidi C, Kischkel FC, et al (1997) FLICE is activated by association with the CD95 death–inducing signaling complex (DISC). EMBO J 16:2794–2804

    Article  PubMed  CAS  Google Scholar 

  60. Eickhoff B, Germeroth L, Stahl C, et al (2000) Trichostatin A–mediated regulation of gene expression and protein kinase activities:reprogramming tumor cells for ribotoxic stress–induced apoptosis. Biol Chem 381: 1127–1132

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, 3204 MERF, University of Iowa, 375 Newton Road, Iowa City, IA, 52242-1089, USA

    Rebecca L. VanOosten, James K. Earel Jr & Thomas S. Griffith

  2. Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA, 52242-1089, USA

    Rebecca L. VanOosten & Thomas S. Griffith

  3. Prostate Cancer Research Group, University of Iowa, Iowa City, IA, 52242-1089, USA

    Thomas S. Griffith

  4. The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242-1089, USA

    Thomas S. Griffith

Authors
  1. Rebecca L. VanOosten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James K. Earel Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas S. Griffith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas S. Griffith.

Additional information

This work was supported by a Young Investigator Award from The Alliance for Cancer Gene Therapy and the National Cancer Institute (CA109446).

Rights and permissions

Reprints and permissions

About this article

Cite this article

VanOosten, R.L., Earel, J.K. & Griffith, T.S. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 12, 561–571 (2007). https://doi.org/10.1007/s10495-006-0009-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-006-0009-9

Keywords

Search

Navigation